{"id":"NCT00989287","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-07","primaryCompletion":"2009-10-09","completion":"2010-10-26","firstPosted":"2009-10-05","resultsPosted":"2018-03-05","lastUpdate":"2019-06-26"},"enrollment":131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK2340272A","otherNames":[]},{"type":"BIOLOGICAL","name":"GSK2340269A","otherNames":[]}],"arms":[{"label":"GSK2340272A Group","type":"EXPERIMENTAL"},{"label":"GSK2340269A Group","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in adults aged 18 to 60 years.","primaryOutcome":{"measure":"Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California/7/2009 (H1N1) Virus Strain","timeFrame":"At Day 21","effectByArm":[{"arm":"GSK2340272A Group","deltaMin":60,"sd":null},{"arm":"GSK2340269A Group","deltaMin":44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":1,"countries":["Belgium"]},"refs":{"pmids":["21450978","28446441"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":65},"commonTop":["Pain","Fatigue","Headache","Myalgia","Muscle aches"]}}